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INTRODUCTION 
Background 
Pre-clinical and clinical investigations have shown that pro-inflammatory leukocytes 
regulate the development and progression of a large variety of cancers, including lung, 
breast, colon, prostate, cervical, liver, ovarian, lymphoma and thyroid cancers and some 
pediatric solid malignancies [1-4].  
Tumor-associated macrophages (TAM) play a key role in this process [5-9]. They secrete 
growth factors that support the proliferation of neoplastic cells, along with delivering 
vascular endothelial growth factor (VEGF) to activate tumor angiogenesis [6] and produce 
cytokines and extracellular proteases to support tumor invasion and metastasis [8].  
TAM originate from circulating monocytes which are recruited to the tumor site and 
programmed by tumor-derived factors such as colony-stimulating factor-1 (CSF-1), 
vascular endothelial growth factor A (VEGF-A) and CC chemokine ligand 2 (CCL2) [10-
11]. These and other factors in the tumor microenvironment shape the TAM phenotype 
and skew them toward tumor-supportive M2-polarized macrophages, although M1-
polarized TAM with anti-tumor activity were also reported in several types of cancer [12-
15].  
Tumor supporting functions of TAM includes the stimulation of tumor cell growth and 
the creation of favorable conditions for tumor cell intravasation into vessels and metastatic 
spread. 
There is a growing set of evidence that specific subpopulations of TIE2 receptor expressing 
monocytes (TEM) in mice and humans significantly contribute to tumor angiogenesis [16-
19]. These monocytes/macrophages are attracted into the tumors by endothelial cell (EC)-
derived cytokine angiopoietin-2 (ANG-2), which interacts with its receptor TIE2 [20]. 
These cells had a signature of M2-polarized macrophages and expressed a panel of 
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markers including CD163, IL-10 and macrophage scavenger receptor-1 (MSR-1). Recently 
it was demonstrated that macrophages generated from CD16-positive monocytes (isolated 
by no-touch procedures) maintain a differential expression pattern and show higher 
phagocytosis activity when compared with macrophages, which were derived from the 
classical monocytes (CD14-positive) [21].  
A recent immunological analysis revealed that TIE2(+)/CD31(+) macrophages constitute 
the predominant population of TAMs that infiltrate metastatic lymph nodes, distinct from 
tissue or inflammatory macrophages [22]. Importantly, these TIE2(+)/CD31(+) 
macrophages also heavily infiltrated metastatic lymph nodes from human breast cancer 
biopsies but not reactive hyperplastic lymph nodes. Thus, TIE2(+)/ CD31(+) macrophages 
may be a unique histopathological biomarker for detecting metastasis in clinical diagnosis, 
and a novel and promising target for TAM-specific cancer therapy.  
Thus, it becomes increasingly important to identify patients whose tumors are heavily 
infiltrated by TEM/TAM, in order to stratify these patients to TEM/TAM depleting 
therapies and to monitor response to these new therapies.  
To serve this goal, a noninvasive and easily repeatable imaging test would be 
advantageous over invasive biopsy.  
The development of tumor specific imaging agents is highly desirable, as they may 
provide earlier and more accurate diagnosis, improve the assessment of the biological 
aggressiveness of the evaluated tumors, stratify patients basing on their immunoresponse 
and monitor treatment. 
 
Cellular Imaging with USPIO MRI 
In the era of personalized medicine, where drug delivery is a key issue, cell tracking 
would have a main role.  
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Cell tracking is extremely challenging and a standard method is no currently available: 
bioluminescence [23-24], radioisotopes [25-27] and Magnetic Resonance Imaging (MRI) 
[24, 1, 2] are among the most used techniques.  
MRI has some inherent interesting characteristics: it combines high-spatial resolution with 
excellent soft tissue contrast while avoiding ionizing radiation.  
A MRI contrast agent, consisting of a suspension of ferric ultrasmall superparamagnetic 
iron oxide particles (USPIO), has demonstrated a superparamagnetism resulting in T1, T2 
and T2* shortening effects, similar to any other MR contrast agent; however, the 
carbohydrate shell results in a prolonged intravascular half life (1-2 days). 
After injection the carbohydrate shell of the complex isolates the bioactive iron oxide core 
from plasma components until the whole iron-carbohydrate complex is taken up by 
reticuloendothelial system (RES) macrophages of the liver, spleen and bone marrow via 
phagocytosis within 24-36 hours [23-26].  
This macrophage-dependent accumulation within the RES has been exploited to more 
accurately characterize both primary malignancies and metastatic disease [27]. 
Laghi et coll. previously reported that significant T2-effects in tumors on delayed MR 
images, acquired at 24 h post-contrast, corresponded to USPIO uptake and retention by 
TAM as revealed by immunohistopathology [25].  
However, little is known regarding the association between macrophage polarization and 
USPIOs accumulation. Therefore, the aim of the present study was to evaluate if there are 
any differences in USPIO labeling for different macrophage populations. 
 
Research Project 
The aim of the present study was to evaluate if there are any differences in USPIO labeling 
for different macrophage populations. 
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- The primary objective of this study is the evaluation in vitro of P904 interaction with 
different macrophagic population (THP-1 cells M1/M2 polarizated and incubated with 
P904) using a 3T clinical scan; the light microscopy and the transmission electric 
microscopy were considered the gold standard. 
- Second, the same MRI protocol has been used for the evaluation of P904 interaction with 
different macrophagic population (M1/M2 polarizated from healthy volunteer and from 
patient with cholangiocarcinoma). 
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MATERIALS & METHOD 
TPH-1 Cell differentiation  
Human Monocyte/Macrophage THP-1 cells (ATCC TIB-202) were maintained in culture 
in RPMI 1640 culture medium (Invitrogen) containing 10% of heat inactivated fetal bovine 
serum (Invitrogen) and supplemented with 10 mM Hepes (Gibco, #15630-056), 1 mM 
pyruvate (Gibco, #11360-039), 2.5 g/l D-glucose (Merck) and 50 pM ß-mercaptoethanol 
(Gibco; 31350–010). THP-1 monocytes were differentiated into macrophages using 320 nM 
of phorbol 12-myristate 13-acetate, PMA (Sigma), and polarized according to the modified 
method of Tjiu [26].  
In order to obtain M1 polarization, cells were treated with PMA for 6 hours and then 
cultured with PMA plus LPS (10 ng/mL, Sigma) and IFN-γ (20 ng/mL, R&D System) for 
another 24 hours; for M2 polarization, cells were treated with PMA for 6 hours and then 
cultured with PMA plus IL-4 (20 ng/mL, R&D System) and IL-13 (20 ng/mL, R&D 
System) for another 24 hours.  The control population of macrophages, which received no 
stimuli, were differentiated from THP-1 cells with 48 hours of incubation using PMA.  
 
Fig.1 TPH-1 cells with 48 hours of incubation using PMA 
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RT-qPCR 
After differentiation, total RNA was extracted using the RNeasy mini kit and DNase 
protocol (Qiagen). mRNA contained in 2 µg total RNA was reverse transcribed using a 
High Capacity RNA-to-cDNA kit (Applied Biosystems). Amplification reaction assays 
contained SYBRGreen PCR Master Mix (Applied Biosystem), primers iNOS (NM_010927, 
Forward: TTCTGTGCTGTCCCAGTGAG; Reverse: TGAAGAAAACCCCTTGTGCT) and 
Mcr1 (NM_008625, Forward: ATATATAAACAAGAATGGTGGGCAGT; Reverse: 
TCCATCCAAATGAATTTCTTATCC). RPS9 (40S ribosomal protein S9) was used as the 
reference gene for normalization, and mRNA abundance was quantified using the 
threshold cycle method. Quantitative PCR assay was performed on an ABI 7500 Fast Real-
Time PCR System. All PCR reactions were performed in triplicate for this target gene and 
the internal control.  
Relative gene expressions were presented with the -2ΔΔCt method. 
 
Human Cell Differentiation 
Peripheral blood (PB) was obtained from healthy volunteers and from patient with 
cholangiocarcinoma, following informed consent.  
Total leukocytes were analyzed after lysis of erythrocytes using ammonium chloride. 
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque gradient 
[17].  
Subsequently the monocyte subsets classical, intermediate and nonclassical monocytes 
were gated based on their surface expression pattern [17]: 
- CD14 + (LPS receptor) and CD16 - (FC III receptor) monocytes that mediate 
inflammatory responses called “inflammatory” monocytes 
- CD14+ (LPS receptor) CD16+ (FC III receptor) cells are subset that are thought to 
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represent the precursors of tissue-resident macrophages and are referred to as “resident” 
monocytes.  
 
 
Cell labeling 
M1-polarized and M2-polarized macrophages were incubated with USPIO research 
prototype (P904, Chematech Guerbet Research, Aulnay-Sous-Bois, France) (200 µg Fe/mL) 
for 36 hours of the 2-day treatment with polarizing stimuli administered at 37°C in 5% 
CO2, basing on Chematech guidelines [28]. 
At least 1x106 cells per milliliter were placed in 2 mL gel phantoms made with 1.6% 
agarose gel. 
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P904 
Molecular characteristics 
x Hydrodynamic size: diameter is 25-30 nm  
x Fe content : > 5000 Fe atoms per particle 
x Recommended dose: 200 µmol/kg = 2.5 µL/g 
Example: for a 30g body weight mouse injection, volume is 
75 µL 
x Relaxivities (data at 37°C; 4% Human Albumin Serum, medium 
closed to plasma) 
Bo (T) 1.5 3.0 4.7 7.0 
r1 (s-1.mM-1) 14±1 7±1 4±0.5 1.6±0.2 
r2 (s-1.mM-1) 90±5 90±5 92±5 94±5 
x Qualitative techniques: Perl’s staining  
x In vitro quantification techniques: P904 is a Fe-based contrast 
agent. Thus, it is necessary to take into account the endoge-
nous iron content for quantification in biological media by ICP-
AES or ICP-MS. Another way for USPIO quantification is rela-
xometry, which is poorly sensitive to endogenous iron content. 
Characteristics of the vial 
x Concentration: [Fe] = 4.47 mgFe/mL Æ [Fe] = 80 mmol/L 
(MFe=56 g/mol) 
x Volume: 450 µL (5-mice dose approx.) 
x Other animal species: please contact us 
Pharmacokinetics/Biodistribution 
 
Species Doses (µmolFe/kg) 
T1/2 
(min) 
Vd 
(mL/kg) 
Cl 
(mL/min/kg) 
Mice 100 62 66 0.80 
Rat 200 145±28 38±2 na 
Rabbit 
150 136±18 22±2 0.06±0.01 
350 164±12 22±0 0.05±0.00 
1000 220±6 22±0 0.04±0.00 
Monkey 85 D= 1h E=16.5h E=2500 0.62 
 
Storage 
Need to be stored at 4°C in a closed vial and away from light. 
 
Legal conditions of use: see Chematech terms and conditions 
of sales 
Contacts: info@chematech-mdt.com   
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P904 is a Ultra Small Particle of Iron Oxide (USPIO) Guerbet Re earch Prototype designed for macrophage imaging. P904 c n 
be used in pre-clinical studies in several applications such as in cell labeling and trafficking, inflammation imaging, 
angiography and high sensitivity contrast-enhanced brain functional MRI (fMRI). 
In vitro Macrophage uptake [1] 
 
Incubation concentration Incubation time THP-1 cell line 
200 µgFe/mL 24 hr 1.8-2.3 pgFe/cell 
 
! For in vitro or animal use only! 
Main applications 
x Cellular Imaging: in vitro cell labeling, cell trafficking, lymph 
node and liver imaging, imaging of inflammation after iv 
injection (atherosclerotic plaque, Alzheimer disease, multiple 
sclerosis, osteo-arthritis…) 
x Blood pool imaging: CE-fMRI, bolus and steady state T1w-
MRA, quantification of cerebral blood volume or vessel size 
index (VSI) 
Examples of applications 
 
MR Angiography 
High Resolution P904 enhanced-MRA in 
Rabbit during the bolus or at steady state [2] 
 
MR lymphography 
P904-enhanced MR lymphography  
in Rabbit [3] 
 
Inflammation imaging 
Atherosclerotic Plaque model  
in Rabbit [4] 
 
Neuro-Inflammation imaging  
Alzheimer disease mice model [5] 
    
Cellular imaging 
Accumulation of P904 in the phagosomes of 
a macrophage [6] 
Blood volume imaging  
Direct visualization of non-human primate 
subcortical nuclei with P904-enhanced MRI [7] 
Cellular imaging 
P904-enhanced MR imaging allows specific cellular imaging of adipose tissue 
macrophages [8] 
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Fig. 2 In vitro macrophage uptake of P904 basing on Chematech Guerbet Research 
 
P904 is an Ultra Small Particle of Iron Oxide (USPIO) Guerbet Research Prototype 
designed for macrophage imaging.  
P904 can be used in pre-clinical studies in several applications such as in cell labeling and 
trafficking, inflammation imaging, angiograp y and high sensitivity contrast-enhanced 
brain functional MRI (fMRI). 
P904 has been investigated for: 
·Cellular Imaging: in vitro cell labeling, cell trafficking, lymph node and liver imaging, 
imaging of inflammation after iv injection (atherosclerotic plaque, Alzheimer disease, 
multiple scl rosis, osteo-arthritis) [31-33] 
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·Blood pool imaging: CE-fMRI, bolus and steady state T1w-MRA, quantification of 
cerebral blood volume or vessel size index (VSI) [33] 
The molecular characteristics of P904 are [28]: 
·Hydrodynamic size: diameter is 25-30 nm 
·Fe content: > 5000 Fe atoms per particle 
·Recommended dose: 200 μmol/kg = 2.5 μL/g 
Example: for a 30g body weight mouse injection, volume is 75 µL 
·Relaxivities (data at 37°C; 4% Human Albumin Serum, medium closed to plasma) 
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The same protocol has been followed for human cell, both for healthy volunteers M1-like 
and M2-like population and for patient with cholangiocarcinoma M1-like and M2-like 
population. 
 
  
Fig.3 From the left to the right: M1-like macrophage and M2-like macrophage from the patient with 
cholangiocarcinoma; M1-like macrophage and M2-like macrophage from the healthy volunteer. 
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Evaluation of P904 cell labeling  
Evaluation of P904 cell labeling with MRI  
USPIO accumulation was assessed in the four TPH macrophage populations (M1-
polarized macrophage plate incubated with P904; M2-polarized macrophage plate 
incubated with P904; control macrophage plate incubated with P904; control macrophage 
plate non-incubated with P904) using 3T clinical MR scanner (Discovery MR750, GE 
Healthcare, Milwaukee, USA).  
At least 1x106 cells per milliliter were placed in 2 mL gel phantoms made with 1.6% 
agarose gel.  
Cell phantoms were then set in the center of a transmit-receive head coil (eight-channel 
HRBRAIN, GE Healthcare, Milwaukee, USA) within an agarose pad. 
 
MR scan protocol included: 
- Coronal T2* MERGE (FOV: 24; phase FOV 0.80; SL 3.0/0.3; auto tr 938;TE 4.9; FA 2; matrix 
320*224). 
- R2* mapping was obtained using a multigradient-echo sequence, and a series of images 
was reconstructed at different echo times. Thirty-six gradient echoes were used to 
reconstruct a time series of images for R2* determination (160 millisecond [msec] 
repetition time, 1.9 msec interval between two uneven echoes, 30° FA, 256 × 256 spatial 
resolution, 2 mm section thickness, 180 mm field of view). R2 mapping was acquired using 
a multiecho, multisection sequence (eight echoes, 500 msec repetition time, 6.9 msec 
interval between two echoes, 128 × 128 spatial resolution, 2.5 mm section thickness, 180 
mm field of view, 90° flip angle) [27]. 
- Coronal T1 FSPGR 3D (TR 8.1, TE 3.1, 12° flip angle, 256 × 256 spatial resolution, 1.2 mm 
section thickness). 
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The same protocol has been used for human cell labeled with P904 both for healthy 
volunteers M1-like and M2-like population and for patient with cholagiocarcinoma M1-
like and M2-like population. 
 
Evaluation of P904 cell labeling with Light Microscopy (LM).  
In order to evaluate P904 labeling using light microscopy (Carl Zeiss Axioskop-40, 
Thornwood, NY, USA), the cells were cytospun (1,400 rpm for 5 minutes), and the tagged 
cells were collected.  
Cellular USPIO uptake was confirmed by Perls’ Prussian blue staining. 
The cellular iron content was estimated with high power field (HPF) microscopy, and an 
experienced investigator, blinded to MRI data, gauged the cells for any structural changes 
as well as the presence and localization of intracellular iron oxide particles. 
 
Fig.4 Cellular iron content estimated with high power field (HPF) microscopy (40x) in the M2-polarized 
TPH-1 macrophage plate incubated with P904 
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Evaluation of P904 cell labeling with Transmission Electron Microscopy (TEM).  
Macrophages were detached and transferred in the Eppendorf tubes for transmission 
electron microscopy (TEM) processing.  
After centrifugation, the cell pellet was fixed with 2.5% glutaraldehyde (SIC, Rome, Italy) 
in 0.1M PBS for two days at 4°C and then rinsed with PBS.  Afterwards, samples were 
post-fixed using 1.33% osmium tetroxide (Agar Scientific, Stansted, UK) for 2 hours and 
rinsed again in PBS.  
The specimens were dehydrated by exchange with ethanol (30%, 70%, 95%, 100% v/v x 3), 
immersed in propylene oxide (BDH Italia, Milan, Italy) for solvent substitution and 
embedded in epoxy resin Embed-812 (SIC, Rome, Italy).   
Semithin (1µm) and ultrathin (80-90nm) sections were obtained using an ultramicrotome 
(Leica EM UC6, Vienna, Austria); for the LM analysis, the semithin sections were collected 
on slides and stained blue by Azur II, and imaging was performed using a light 
microscope (Carl Zeiss Axioskop-40, Thornwood, NY, USA).  
Whereas for the TEM observation, the ultrathin sections were collected on 100-mesh 
copper grids (Assing, Rome, Italy) stained with a rare-earth elements solution and lead 
citrate. Imaging was performed using a transmission electron microscope set with an 
accelerating voltage of 60kV (Carl Zeiss EM10 , Thornwood, NY, USA) while images were 
acquired using a digital camera (AMT CCD, Deben UK Ltd, Suffolk, UK).  
An experienced investigator, blinded to MRI data, gauged the cells for any structural 
changes as well as the presence and localization of intracellular iron oxide particles. 
 
Data analysis 
MRI data analysis 
Two radiologists were blinded and MR images (considered as adequate) were 
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independently read.  
The primary evaluation criteria included observing changes in every plate, and in 
particular, the presence of slope effect was appraised.  
At least 10 ROI measurements for every single plate were performed for the evaluation of 
T1w, T2*w and R* datasets. Multisection, multiple-echo, quantitative R2* data were 
evaluated using FuncTool 4.5.3 (GE Healthcare, Milwaukee, USA). 
 
LM and TEM data analysis 
An experienced investigator, blinded to MRI data, gauged the cells for any structural 
changes as well as the presence and localization of intracellular iron oxide particles both in 
LM dataset and in TEM dataset. 
 
Statistical Analysis 
For each population, measurements were averaged and results reported as a mean ± 
standard deviation. A 95% interval of confidence (IC) was also calculated and presented. 
Normal distribution of the data was determined by using the Shapiro-Wilk test.  
For each MRI parameter (T1, T2, R*), results among the four different populations were 
analyzed and compared using the repeated measurements of analysis of variance.  
Cellular iron content in the three populations was evaluated and compared as well by 
using repeated measurements of analysis of variance.  
A p value < 0.05 was considered statistically significant.  
All of the analyses were performed using SPSS (version 22.0, SPSS Inc, Chicago, IL, USA).
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RESULTS 
Human THP-1 monocytes were differentiated into macrophages by incubation in the 
presence of PMA. Cells became adherent and the expression of recognized macrophage 
markers, CD68 (cluster of differentiation 68), were analyzed by immunofluorescence 
staining, and based upon the literature, we polarized macrophages in M1 and M2 
phenotype. Macrophage M1 and M2 polarization was confirmed by measuring the 
expression of classical M1 markers: iNOS for M1 and Mannose receptor 1 (Mrc1) at the 
mRNA level using RT-qPCR (Table 1). 
 
 
 
Table 1 Macrophage M1 and M2 polarization assessment evaluated with the expression of M1 markers: 
iNOS for M1 and Mannose receptor 1 (Mrc1) at the mRNA level using RT-qPCR . 
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The T1 signal for the M2-polarized population (1982.0 ± 54.2, 95% IC 1912.8-2048.1) was 
significantly higher compared to both the M1-polarized population (740.5 ± 32.1, 95% IC 
705.5-775.4, p<0.0001) and the M0-P904 population (769.7 ± 40.0, 95% IC 743.8-795.5, 
p<0.0001). The T1 signal in the M0 population (411.3 ± 25, 95% IC 405.8-415.2) was 
significantly lower compared to all of the populations (all p<0.0001). No significant 
differences were observed between M1 and M0-P904 (p=0.99).  
The T2* signal for the M0 population (1050.6 ± 66.1, 95% IC 1.32.7-1068.4) was significantly 
higher compared to the M0-P904 (919.9 ± 57.8, 95% IC 891.5-936.3, p<0.0001), M1-polarized 
(1004.1 ± 68.9, 95% IC 998.6-1009.5, p<0.0001) and M2-polarized populations (576.6 ± 37.6, 
95% IC 565.5-587.5, p<0.0001). The T2 signal for the M2-polarized population was 
significantly lower compared to the other groups (all p<0.0001). 
R* was significantly higher for the M2-polarized population (68.1 ± 6.0, 95% IC 64.1-72.0) 
compared to the other populations (all p<0.0001), while R* was significantly lower for M0 
(3.7 ± 1.3, 95% IC 0.8-6.6) compared to M0-P904 (16.9 ± 3.2, 95% IC 15.4-18.7, p<0.001). No 
significant differences were found between the M1-polarized population (6.5 ± 3.7, 95% IC 
5.4-7.5) and the M0 population (p=0.31) (Figure 5). 
 
 
 
 
 
 
 
 
 
Fig5 USPIO MR. M2-polarized population showing high signal on T1 weighted images and low signal in T2* 
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M2 phantom demonstrated the slope effect after 48 hours of incubation non visible in the 
other populations. 
 
Fig 6 Slope effect has been demonstrated in the M2 polarized population and it is more noticeable when the 
TE is higher. 
 
Cellular iron content was evaluated in the M1-polarized, M2-polarized and M0 P904 
population. 
The number of macrophages with iron content in the M2-polarized population was 32.1 ± 
8.5 (95% IC 28.1-43.8) significantly higher when compared to both the M1 polarized 
population (20.3 ± 7.1, 95% IC 12.2-28.2, p=0.04) and the M0-P904 population (2.3 ± 1.1, 
95% IC 1.0-3.6, p=0.003).  
Significant differences were also observed and reported by comparing the M1-polarized 
population to the M0-P904 population (p=0.005). 
 
The TEM demonstrated a ubiquitous distribution of P904 within the cellular 
compartments including cytoplasm, mitochondria, plasmatic/nuclear membranes and 
nucleolus (Figure 2). 
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Fig 7 Transmission electron microscopy (TEM) images of Human Monocyte Macrophage THP-1 cells 
incubated with ferric ultrasmall supermagnetic iron oxide particles (USPIO) research prototype P904. The 
images show the phagocytosis of USPIO and its localization was observed in several districts (black arrows): 
cytoplasm [a-f], mitochondria [a, d, e], plasmatic/nuclear membranes [a, d, f], and nucleolus [e, f]. 
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Same results were validated also in the macrophage populations derived from human cell. 
 
 T1  T2* R* 
PZ M1 
polarized+P904 
950,87 ± 203,83 360,84 ± 111,31 119,02± 25,26 
PZ M2 
polarized+P904 
1514,63 ± 397,31 78,46 ± 18,66 147,97± 33,82 
 
HV M1 
polarized+P904 
947,58 ± 261,77 287,13± 108,20 79,94 ± 34,33 
HV M2 
polarized+P904 
930 ± 274,33 85,36 ± 25,32 136,99 ± 42,28 
 
  
Table 2 MRI signal of cell from patient with cholangiocarcinoma (PZ) and from healthy volunteer (HZ) 
 
The T1 signal for the M2-polarized population from the patient with cholangiocarcinoma 
was significantly higher compared to both the M1-polarized population and the M2-
polarized population from healthy volunteer. 
The T2* signal for the M2-polarized population was significantly lower compared to the 
other groups in particular for M2-polarized population from the patient with 
cholangiocarcinoma. 
R* was significantly higher for the M2-polarized population compared to the other 
populations. 
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DISCUSSION 
The present study demonstrated the possibility to differentiate macrophage populations, 
in particular M1- and M2-polarized, based on the different labeling efficiencies, when 
incubated with an USPIO (P904) MR contrast agent.  
After P904 incubation, T1 signal shown by M2-polarized population was significantly 
higher compared to the other population (p<0.0001), and T2* signal for M2-polarized 
macrophages was significantly lower compared to the other group of cells (p<0.0001) 
(Figure 1). Although R* seemed to depend on the number of labeled cells in vitro, it was 
significantly higher for M2 population as compared to other sub-groups (p<0.0001) [27]. 
LM confirmed MRI results as it demonstrated higher iron content in M2-polarized 
population compared to both M1-polarized population (p=0.04) and M0-P904 population 
(p=0.003). P904 particles were demonstrated to be ubiquitous in all cellular compartments, 
instead of the dogma of USPIO localization within the RES. 
The results were confirmed using the same protocol with macrophage population derived 
from human PB. 
 
These preliminary results are interesting, particularly in oncology, considering the 
importance of macrophages in tumor regulation, as demonstrated by many recent pre-
clinical and clinical investigations [1-3].  Tumor-Associated Macrophages (TAM) originate 
from circulating monocytes and have a complex role in the carcinogenic process, since 
they participate in immune response to tumors in a polarized manner: classic M1 
macrophages promote tumoricidal responses, whereas M2 macrophages, secreting growth 
factors that support the proliferation of neoplastic cells, delivering vascular endothelial 
growth factor (VEGF) to activate tumor angiogenesis, and producing cytokines and 
extracellular proteases, support tumor invasion and metastasis [5-7,27].  
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Modulation of TAM is one of the goals of the research in the attempt to skew TAM 
polarization into cells with a proinflammatory antitumor phenotype. Deep knowledge of 
the regulation of TAM functions would be essential for the development of innovative 
anticancer strategies [34].  
As a consequence, the availability of a MR contrast medium able, in vivo, to label M2-
polarized macrophages would be extremely important in assessing response to therapy. 
This would be crucial in the case of immunotherapy.  
As it is well known from clinical practice, imaging evaluation of response to 
immunotherapy is difficult and late [35-36]. 
That the possibility of USPIO MR contrast agent are not only a dream, but a potential 
possibility comes from an old observation of our group, which was able to demonstrate a 
significant decrease of signal intensity of myometrium and cervical stroma of the uterus 
after USPIO particles administration in a group of patients affected by uterine cancers [25]. 
At that time we were unable to correlate this finding with the presence of TAM and on the 
basis of knowledge about pharmacological properties of the USPIO agent we were unable 
to provide a definite explanation of this phenomenon [37]. In fact, no macrophages are 
normally present within myometrium or cervical stroma, being able to uptake the contrast 
medium and to determine a decrease of signal intensity of both the tissues.  
The absence of macrophages within cervical stroma and myometrium was also confirmed 
by a re-evaluation of pathologic specimens available in our cases. Thus, we focused our 
attention only on the radiological benefits of better conspicuity of the lesion and 
consequently better local staging.  
In the light of today’s knowledge, that was the first observation of labeled TAM, although 
if they were M2-polarized macrophages only is still unknown. 
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CONCLUSION 
In conclusion, selective USPIO labeling was successfully demonstrated in the M2-
polarized population. 
The added value of the research is that it was conducted using a clinical 3.0T MR scanner, 
making further studies available for larger groups of researchers. 
 Further studies on same topic would be highly desirable to investigate the possible role of 
non-invasive diagnosis in inflammation and cancer imaging, basing on different USPIO 
labeling - and involvement - of M1 and M2 population. 
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